Actelion Names Muller as CFO as Oakley Leaves Swiss Drugmaker

Actelion Ltd., the Swiss drugmaker that gets almost 90 percent of sales from a treatment for a rare lung disease, said Andre Muller will replace Chief Financial Officer Andrew Oakley, who is leaving the company.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.